PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS
Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.
We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.
Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.
STATE OF THE ART CRO FACILITIES
Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.
High success rate customer satisfaction in 2021: 97.5%
When is your turn?
THEY TRUST US
We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies
LATEST NEWS ABOUT PHYSIOGENEX
Physiogenex to present its obese NASH hamster model at the 2nd HFpEF Summit in Boston, MA, Jan. 25-26, 2023
Physiogenex will be presenting its innovative obese NASH hamster model at the 2nd HFpEF Summit in Boston, MA, USA, January 25-26, 2023. This unique...
Physiogenex is delighted to be awarded ISO 9001:2015, a globally recognized certification of quality management system standards. Our scope of certification «...
Physiogenex to present its obese NASH hamster model at the 20th World Congress of Insulin Resistance in Los Angeles, CA, Dec 1-3, 2022
Physiogenex will be presenting its innovative obese NASH hamster model at the 20th World Congress of Insulin resistance, Los Angeles, CA, USA, Dec.1-3, 2022....